MOUNTAIN VIEW, Calif.,
April 13, 2021 /PRNewswire/ -- Aditx
Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a
biotech innovation company focused on improving the health of the
immune system, today announced that Sunny
Uberoi has joined the organization as its Chief
Communications Officer. Uberoi joins Aditxt to raise the company's
profile in advance of initiating its first-in-human clinical trials
and support the rapid scaling of AditxtScore, a commercial
technology platform designed to provide a personalized,
comprehensive profile of the immune system. In this new role,
Uberoi will be responsible for leading global corporate
communications, investor relations, and government
affairs.
"Aditxt is a strong purpose-led brand with an emerging community
of stakeholders around the world. To achieve our commitments to
growing our brand authentically, we need the right executives to
support our mission and business model. Sunny brings a unique
combination of senior leadership experience in healthtech,
financial services and biopharmaceuticals, and his guidance will be
critical to the next phase of growth for our company," said
Amro Albanna, co-founder and CEO of
Aditxt. "
Most recently, Uberoi served as the Vice President of Corporate
Affairs for Global Drug Development, Research and Early
Development, and Global Product Supply at Bristol Myers Squibb.
Uberoi also led communications for S&P Global Market
Intelligence, including the asset divesture of J.D. Power. Before
that, he was the Head of Corporate Stakeholder Engagement at
Deloitte as well as the Head of Global Communications for Consumer
Health at Pfizer.
Uberoi earned his bachelor's degree in Economics from The
Manchester Metropolitan University
and a Master's degree in Marketing from The University of
Manchester.
About Aditx Therapeutics
Aditxt is developing
technologies specifically focused on improving the health of the
immune system through immune monitoring and reprogramming. The
immune monitoring technology is designed to provide a personalized
comprehensive profile of the immune system. The immune
reprogramming technology is currently at the pre-clinical stage and
is designed to retrain the immune system to induce tolerance with
an objective of addressing rejection of transplanted organs,
autoimmune diseases, and allergies. For more information, please
visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of the federal securities laws. Forward looking statements
include statements regarding the Company's intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the Company's ongoing and planned product
development; the Company's intellectual property position; the
Company's ability to develop commercial functions; expectations
regarding product launch and revenue; the Company's results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section titled "Risk Factors" in the Company's
most recent Annual Report on Form 10-K, as well as discussions of
potential risks, uncertainties, and other important factors in the
Company's other filings with the Securities and Exchange
Commission. All such statements speak only as of the date made, and
the Company undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aditxt-therapeutics-names-sunny-uberoi-as-its-first-chief-communications-officer-301267059.html
SOURCE Aditxt